Lindsay Ratner1, Jing 'Daisy' Zhu1, Megan N Gower1, Tejendra Patel1, Jordan A Miller2, Amber Cipriani1,2, George A Stouffer3,4, Daniel J Crona1,2,5, Craig R Lee1,3,4. 1. Division of Pharmacotherapy & Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. 2. Department of Pharmacy, University of North Carolina Hospitals & Clinics, Chapel Hill, NC, USA. 3. Division of Cardiology, UNC School of Medicine, University of North Carolina, Chapel Hill, NC, USA. 4. McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA. 5. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Abstract
Aim: To evaluate the potential impact of preemptive multigene pharmacogenomic (PGx) testing on medication prescribing in real-world clinical settings. Patients & methods: Prescription frequencies for 65 medications with actionable PGx recommendations were collected in 215 percutaneous coronary intervention (PCI) and 131 allogeneic hematopoietic cell transplant (allo-HCT) patients. A simulation projected the number of PGx-guided prescribing opportunities. Results: In PCI and allo-HCT patients, respectively, 66.5 and 90.1% were prescribed at least one medication with actionable PGx prescribing recommendations. Simulations projected 26.5 and 41.2 total PGx-guided prescribing opportunities per 100 PCI and allo-HCT patients, respectively, if multigene PGx results were available. Conclusion: A multigene PGx testing strategy offers potential to optimize medication prescribing beyond clopidogrel and tacrolimus in PCI and allo-HCT patients.
Aim: To evaluate the potential impact of preemptive multigene pharmacogenomic (PGx) testing on medication prescribing in real-world clinical settings. Patients & methods: Prescription frequencies for 65 medications with actionable PGx recommendations were collected in 215 percutaneous coronary intervention (PCI) and 131 allogeneic hematopoietic cell transplant (allo-HCT) patients. A simulation projected the number of PGx-guided prescribing opportunities. Results: In PCI and allo-HCT patients, respectively, 66.5 and 90.1% were prescribed at least one medication with actionable PGx prescribing recommendations. Simulations projected 26.5 and 41.2 total PGx-guided prescribing opportunities per 100 PCI and allo-HCT patients, respectively, if multigene PGx results were available. Conclusion: A multigene PGx testing strategy offers potential to optimize medication prescribing beyond clopidogrel and tacrolimus in PCI and allo-HCT patients.
Authors: Rachel M Black; Alexis K Williams; Lindsay Ratner; Daniel J Crona; Tim Wiltshire; Karen E Weck; George A Stouffer; Craig R Lee Journal: Pharmacogenomics Date: 2020-04-28 Impact factor: 2.533
Authors: K A Birdwell; B Decker; J M Barbarino; J F Peterson; C M Stein; W Sadee; D Wang; A A Vinks; Y He; J J Swen; J S Leeder; Rhn van Schaik; K E Thummel; T E Klein; K E Caudle; I A M MacPhee Journal: Clin Pharmacol Ther Date: 2015-06-03 Impact factor: 6.875
Authors: Craig R Lee; Vindhya B Sriramoju; Alexandra Cervantes; Lucius A Howell; Nicholas Varunok; Shivanshu Madan; Kasey Hamrick; Melissa J Polasek; John Andrew Lee; Megan Clarke; Jonathan D Cicci; Karen E Weck; George A Stouffer Journal: Circ Genom Precis Med Date: 2018-04
Authors: Larisa H Cavallari; Craig R Lee; Amber L Beitelshees; Rhonda M Cooper-DeHoff; Julio D Duarte; Deepak Voora; Stephen E Kimmel; Caitrin W McDonough; Yan Gong; Chintan V Dave; Victoria M Pratt; Tameka D Alestock; R David Anderson; Jorge Alsip; Amer K Ardati; Brigitta C Brott; Lawrence Brown; Supatat Chumnumwat; Michael J Clare-Salzler; James C Coons; Joshua C Denny; Chrisly Dillon; Amanda R Elsey; Issam S Hamadeh; Shuko Harada; William B Hillegass; Lindsay Hines; Richard B Horenstein; Lucius A Howell; Linda J B Jeng; Mark D Kelemen; Yee Ming Lee; Oyunbileg Magvanjav; May Montasser; David R Nelson; Edith A Nutescu; Devon C Nwaba; Ruth E Pakyz; Kathleen Palmer; Josh F Peterson; Toni I Pollin; Alison H Quinn; Shawn W Robinson; Jamie Schub; Todd C Skaar; D Max Smith; Vindhya B Sriramoju; Petr Starostik; Tomasz P Stys; James M Stevenson; Nicholas Varunok; Mark R Vesely; Dyson T Wake; Karen E Weck; Kristin W Weitzel; Russell A Wilke; James Willig; Richard Y Zhao; Rolf P Kreutz; George A Stouffer; Philip E Empey; Nita A Limdi; Alan R Shuldiner; Almut G Winterstein; Julie A Johnson Journal: JACC Cardiovasc Interv Date: 2017-11-01 Impact factor: 11.195
Authors: L H Cavallari; A L Beitelshees; K V Blake; L G Dressler; J D Duarte; A Elsey; J N Eichmeyer; P E Empey; J P Franciosi; J K Hicks; A M Holmes; Ljb Jeng; C R Lee; J J Lima; N A Limdi; J Modlin; A O Obeng; N Petry; V M Pratt; T C Skaar; S Tuteja; D Voora; M Wagner; K W Weitzel; R A Wilke; J F Peterson; J A Johnson Journal: Clin Transl Sci Date: 2017-03-14 Impact factor: 4.689
Authors: Nicholas J Keeling; Meagen M Rosenthal; Donna West-Strum; Amit S Patel; Cyrine E Haidar; James M Hoffman Journal: Genet Med Date: 2017-10-26 Impact factor: 8.822
Authors: Catherine Chanfreau-Coffinier; Leland E Hull; Julie A Lynch; Scott L DuVall; Scott M Damrauer; Francesca E Cunningham; Benjamin F Voight; Michael E Matheny; David W Oslin; Michael S Icardi; Sony Tuteja Journal: JAMA Netw Open Date: 2019-06-05
Authors: D Max Smith; Beth N Peshkin; T Blaise Springfield; Ryan P Brown; Elizabeth Hwang; Susanna Kmiecik; Richard Shapiro; Zayd Eldadah; Conor Lundergan; Joel McAlduff; Bonnie Levin; Sandra M Swain Journal: Clin Transl Sci Date: 2020-02-12 Impact factor: 4.689
Authors: Julio D Duarte; Rachel Dalton; Amanda L Elchynski; D Max Smith; Emily J Cicali; James C Lee; Benjamin Q Duong; Natasha J Petry; Christina L Aquilante; Amber L Beitelshees; Philip E Empey; Julie A Johnson; Aniwaa Owusu Obeng; Amy L Pasternak; Victoria M Pratt; Laura B Ramsey; Sony Tuteja; Sara L Van Driest; Kristin Wiisanen; J Kevin Hicks; Larisa H Cavallari Journal: Genet Med Date: 2021-07-19 Impact factor: 8.822